Crinetics Pharmaceuticals, Inc. entered into non-compete agreements with key employees, including CEO R. Scott Struthers, Ph.D., CFO Tobin Schilke, CSO Stephen Betz, Ph.D., and CCO Isabel Kalofonos, following its merger agreement with Vertex Pharmaceuticals Incorporated. The restricted parties will be subject to one-year non-compete restrictions for a period of one year following the merger closing date. Tobin Schilke, Stephen Betz, and Isabel Kalofonos will receive cash payments of $140,000, $30,000, and $30,000, respectively, upon the merger closing. Crinetics Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing therapeutic solutions for rare diseases.

Crinetics Pharmaceuticals, Inc. entered into a merger agreement with Vertex Pharmaceuticals Incorporated and Clark Merger Sub, Inc. on July 6, 2026, to be acquired for $85.00 per share in cash. The transaction is expected to close in the third quarter of 2026, subject to stockholder approval and regulatory clearances. Crinetics Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing therapies for rare endocrine diseases.